ASIA-PACIFIC INSULIN DELIVERY DEVICES MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The market is segmented by Product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump), and Geography.

Market Snapshot

Asia-Pacific insulin delivery devices market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >3 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

Asia-Pacific insulin delivery devices market is expected to register a CAGR of more than 3% during the forecast period. The Asia-Pacific region has witnessed an astounding increase in the prevalence of diabetes in patients, in recent years. The increasing demand for insulin has led to great R&D in manufacturing different, painless types of insulin deliverable devices, like CGM-integrated insulin pumps. Traditionally, insulin syringes were the only form of insulin delivery systems, which were considered to be painful and not user-friendly. Furthermore, the dosage may not be accurate. Thus, companies, like Novo Nordisk and Sanofi, among others, have bought their insulin pens in the market. These pens have a specific set of dosages and are considered to be not only less painful to use, but also reduce wastage of insulin. The high cost of insulin pens is the only prominent restraining factor for the growth of the pens market.

Scope of the Report

The study provides a detailed analysis of the insulin delivery devices market in the Asia-Pacific region and includes market share, size, forecast, and industry overview.

By Product (Value and Volume, 2016 - 2026)
Cartridges in Reusable Insulin Pens
Disposable Insulin Pens
Insulin Syringes
Insulin Jet Injectors
Insulin Pump
Insulin Pump Device
Insulin Pump Reservoir
Infusion Set
Geography (Value and Volume, 2016 - 2026)
Asia-Pacific
Australia
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
India
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Indonesia
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Thailand
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Philippines
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Vietnam
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
China
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
South Korea
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Japan
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Malaysia
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)
Rest of Asia-Pacific
By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

Report scope can be customized per your requirements. Click here.

Key Market Trends

Japan Holds the Major Market Share in the Asia-Pacific Insulin Delivery Devices Market in the year 2020

Japan accounted for 41% of the market share in the Asia-Pacific insulin delivery devices market. In developing countries, such as Japan, China, and India, the rate of diabetes among the population has been growing, mainly due to the unhealthy lifestyle of the population. In Japan, the increasing geriatric population is driving the insulin delivery devices market. The changing lifestyle trends, coupled with high disposable income among the population, are some of the prominent driving factors for the sales of insulin delivery devices. Insulin was initially considered to be the treatment method only for type-1 patients. However, over the years, insulin has also been used by a considerable number of type-2 patients as a line of treatment.

Asia-Pacific Insulin Delivery Devices Market

Insulin Delivery through Disposable pens is having highest market share in the Asia-Pacific Region.

The Asia-Pacific market for Insulin Disposable pens is valued at USD 6.6 billion in 2020 with 39% of the market share. This contains a prefilled insulin cartridge. Once used, the entire pen unit is thrown away. Insulin in pens and cartridges is generally more expensive than bottled insulin and syringes. Insulin cartridges in reusable pens are known to be a needed extension to insulin pens. When pens are used a small quantity of insulin is wasted, making the process less economical. A large set of diabetic type-1 patients is children. There is a need for an alternative to the existing needle-based delivery system, which is painful, and thus, the invention of an insulin jet injector, a painless insulin delivery system, was introduced. Most types of insulins are manufactured in the form of cartridges, thus, making it easily accessible. ​ These devices have all the functional benefits of reusable pens and are cost-effective, as these cartridges are less expensive when compared to disposable insulin pens in the long run. ​

Asia-Pacific Insulin Delivery Devices Market_devices

Competitive Landscape

The market is consolidated, with few players holding a significant market share in 2020. However, the insulin syringe market is highly fragmented, and many market players are based locally. Companies to expand their market presence are investing in R&D as well as collaborating with other major players to develop innovative solutions. Abbott and Novo Nordisk enter a partnership, in order to provide an integrated digital solution to people with diabetes, using insulin. The collaboration may enable insulin data to be shared between Novo Nordisk's connected insulin pens and digital health tools compatible with the FreeStyle Libre portfolio of products. The Control-IQ system from Tandem was cleared by the FDA at the end of 2019 and launched to customers in January 2020.

RECENT DEVELOPMENTS

In June 2021, Medtronic Korea agreed with Handok to increase the supply of its medical devices for diagnosing and treating diabetes in Korea. The two companies said they signed the deal to introduce differentiated diabetes diagnosis and advanced treatment solutions to Korean patients based on their expertise in the field. Handok will be marketing Medtronic’s continuous glucose monitoring (CGM) system, insulin pump, direct infusion device, and other medical products related to diabetes. Handok had been supplying Medtronic’s CGM systems, Guardian Connect and iPro-2, since June 2019. The recent agreement added insulin pump MiniMed 640G, direct infusion device i-Port Advance, and MiniMed 770G.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. Market Segmentation

    1. 5.1 By Product (Value and Volume, 2016 - 2026)

      1. 5.1.1 Cartridges in Reusable Insulin Pens

      2. 5.1.2 Disposable Insulin Pens

      3. 5.1.3 Insulin Syringes

      4. 5.1.4 Insulin Jet Injectors

      5. 5.1.5 Insulin Pump

        1. 5.1.5.1 Insulin Pump Device

        2. 5.1.5.2 Insulin Pump Reservoir

        3. 5.1.5.3 Infusion Set

    2. 5.2 Geography (Value and Volume, 2016 - 2026)

      1. 5.2.1 Asia-Pacific

        1. 5.2.1.1 Australia

          1. 5.2.1.1.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        2. 5.2.1.2 India

          1. 5.2.1.2.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        3. 5.2.1.3 Indonesia

          1. 5.2.1.3.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        4. 5.2.1.4 Thailand

          1. 5.2.1.4.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        5. 5.2.1.5 Philippines

          1. 5.2.1.5.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        6. 5.2.1.6 Vietnam

          1. 5.2.1.6.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        7. 5.2.1.7 China

          1. 5.2.1.7.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        8. 5.2.1.8 South Korea

          1. 5.2.1.8.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        9. 5.2.1.9 Japan

          1. 5.2.1.9.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        10. 5.2.1.10 Malaysia

          1. 5.2.1.10.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

        11. 5.2.1.11 Rest of Asia-Pacific

          1. 5.2.1.11.1 By product (Cartridges in Reusable Insulin Pens, Disposable Insulin Pens, Insulin Syringes, Insulin Jet Injectors, Insulin Pump)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2026)

    2. 6.2 Type-2 Diabetes Population (2016 - 2026)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Becton and Dickenson

      2. 7.1.2 Medtronic

      3. 7.1.3 Insulet

      4. 7.1.4 Tandem

      5. 7.1.5 Ypsomed Holding

      6. 7.1.6 Novo Nordisk

      7. 7.1.7 Sanofi

      8. 7.1.8 Eli Lilly and Company

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Insulin Delivery Devices Market market is studied from 2016 - 2026.

The Asia-Pacific Insulin Delivery Devices Market is growing at a CAGR of >3% over the next 5 years.

The Asia-Pacific Insulin Delivery Devices Market is valued at 16 Billion USD in 2016.

The Asia-Pacific Insulin Delivery Devices Market is valued at 20 Billion USD in 2026.

Novo Nordisk, Medtronic, Sanofi, Eli Lilly and Company, Ypsomed Holding are the major companies operating in Asia-Pacific Insulin Delivery Devices Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!